← Research
Feb 2018 Phase 2
Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression: A Randomized Clinical Trial
Daly EJ, Singh JB, Fedgchin M, et al. — Janssen Research & Development
Published in JAMA Psychiatry
67 adults with treatment-resistant depression received placebo or one of three intranasal esketamine doses (28/56/84mg) twice weekly for two weeks, alongside their existing antidepressant. Dose-dependent MADRS improvement appeared within a week and held through an 8-week follow-up — pivotal data behind what became Spravato.
Read the Full Paper at JAMA Psychiatry